Skip Nav Destination
How I treat smoldering multiple myeloma
Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011
Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A
Differential impact of allelic ratio and insertion site in FLT3-ITD–positive AML with respect to allogeneic transplantation
Issue Archive
November 27 2014
Table of Contents
INSIDE BLOOD COMMENTARIES
REVIEW ARTICLE
HOW I TREAT
How I treat smoldering multiple myeloma
Clinical Trials & Observations
CLINICAL TRIALS AND OBSERVATIONS
Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011
Clinical Trials & Observations
Peter W. Collins,on behalf of the UK Haemophilia Centre Doctors’ Organization,Benedict P. Palmer,on behalf of the UK Haemophilia Centre Doctors’ Organization,Elizabeth A. Chalmers,on behalf of the UK Haemophilia Centre Doctors’ Organization,Daniel P. Hart,on behalf of the UK Haemophilia Centre Doctors’ Organization,Ri Liesner,on behalf of the UK Haemophilia Centre Doctors’ Organization,Savita Rangarajan,on behalf of the UK Haemophilia Centre Doctors’ Organization,Katherine Talks,on behalf of the UK Haemophilia Centre Doctors’ Organization,Michael Williams,on behalf of the UK Haemophilia Centre Doctors’ Organization,Charles R. M. Hay,on behalf of the UK Haemophilia Centre Doctors’ Organization
Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A
Clinical Trials & Observations
Thierry Calvez,for the FranceCoag Network,Hervé Chambost,for the FranceCoag Network,Ségolène Claeyssens-Donadel,for the FranceCoag Network,Roseline d’Oiron,for the FranceCoag Network,Véronique Goulet,for the FranceCoag Network,Benoît Guillet,for the FranceCoag Network,Virginie Héritier,for the FranceCoag Network,Vanessa Milien,for the FranceCoag Network,Chantal Rothschild,for the FranceCoag Network,Valérie Roussel-Robert,for the FranceCoag Network,Christine Vinciguerra,for the FranceCoag Network,Jenny Goudemand,for the FranceCoag Network
IMMUNOBIOLOGY
LYMPHOID NEOPLASIA
Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition
Julie Irving,Elizabeth Matheson,Lynne Minto,Helen Blair,Marian Case,Christina Halsey,Isabella Swidenbank,Frida Ponthan,Renate Kirschner-Schwabe,Stefanie Groeneveld-Krentz,Jana Hof,James Allan,Christine Harrison,Josef Vormoor,Arend von Stackelberg,Cornelia Eckert
MYELOID NEOPLASIA
Differential impact of allelic ratio and insertion site in FLT3-ITD–positive AML with respect to allogeneic transplantation
Clinical Trials & Observations
Richard F. Schlenk,for the German-Austrian AML Study Group,Sabine Kayser,for the German-Austrian AML Study Group,Lars Bullinger,for the German-Austrian AML Study Group,Guido Kobbe,for the German-Austrian AML Study Group,Jochen Casper,for the German-Austrian AML Study Group,Mark Ringhoffer,for the German-Austrian AML Study Group,Gerhard Held,for the German-Austrian AML Study Group,Peter Brossart,for the German-Austrian AML Study Group,Michael Lübbert,for the German-Austrian AML Study Group,Helmut R. Salih,for the German-Austrian AML Study Group,Thomas Kindler,for the German-Austrian AML Study Group,Heinz A. Horst,for the German-Austrian AML Study Group,Gerald Wulf,for the German-Austrian AML Study Group,David Nachbaur,for the German-Austrian AML Study Group,Katharina Götze,for the German-Austrian AML Study Group,Alexander Lamparter,for the German-Austrian AML Study Group,Peter Paschka,for the German-Austrian AML Study Group,Verena I. Gaidzik,for the German-Austrian AML Study Group,Veronica Teleanu,for the German-Austrian AML Study Group,Daniela Späth,for the German-Austrian AML Study Group,Axel Benner,for the German-Austrian AML Study Group,Jürgen Krauter,for the German-Austrian AML Study Group,Arnold Ganser,for the German-Austrian AML Study Group,Hartmut Döhner,for the German-Austrian AML Study Group,Konstanze Döhner,for the German-Austrian AML Study Group
PLATELETS AND THROMBOPOIESIS
Common variants in the human platelet PAR4 thrombin receptor alter platelet function and differ by race
Leonard C. Edelstein,Lukas M. Simon,Cory R. Lindsay,Xianguo Kong,Raúl Teruel-Montoya,Benjamin E. Tourdot,Edward S. Chen,Lin Ma,Shaun Coughlin,Marvin Nieman,Michael Holinstat,Chad A. Shaw,Paul F. Bray
RED CELLS, IRON, AND ERYTHROPOIESIS
Export of virulence proteins by malaria-infected erythrocytes involves remodeling of host actin cytoskeleton
Melanie Rug,Marek Cyrklaff,Antti Mikkonen,Leandro Lemgruber,Simone Kuelzer,Cecilia P. Sanchez,Jennifer Thompson,Eric Hanssen,Matthew O’Neill,Christine Langer,Michael Lanzer,Friedrich Frischknecht,Alexander G. Maier,Alan F. Cowman
THROMBOSIS AND HEMOSTASIS
TRANSPLANTATION
Inhibition of Akt signaling promotes the generation of superior tumor-reactive T cells for adoptive immunotherapy
Anniek B. van der Waart,Noortje M. P. van de Weem,Frans Maas,Cynthia S. M. Kramer,Michel G. D. Kester,J. H. Frederik Falkenburg,Nicolaas Schaap,Joop H. Jansen,Robbert van der Voort,Luca Gattinoni,Willemijn Hobo,Harry Dolstra
BLOOD WORK
CORRESPONDENCE
-
Cover Image
Cover Image
A protein exported by the malaria parasite Plasmodium falciparum plays a role in remodeling of the host actin cytoskeleton in red blood cells. See the article by Rug et al on page 3459.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkAdvertising
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals